LaFargue, Christopher J.
Amero, Paola http://orcid.org/0000-0002-7503-0381
Noh, Kyunghee
Mangala, Lingegowda S.
Wen, Yunfei http://orcid.org/0000-0001-5313-1117
Bayraktar, Emine
Umamaheswaran, Sujanitha http://orcid.org/0000-0002-3845-9373
Stur, Elaine
Dasari, Santosh K.
Ivan, Cristina
Pradeep, Sunila
Yoo, Wonbeak http://orcid.org/0000-0001-5803-0577
Lu, Chunhua
Jennings, Nicholas B.
Vathipadiekal, Vinod
Hu, Wei
Chelariu-Raicu, Anca
Ku, Zhiqiang http://orcid.org/0000-0001-8347-0013
Deng, Hui
Xiong, Wei
Choi, Hyun-Jin
Hu, Min
Kiyama, Takae
Mao, Chai-An
Ali-Fehmi, Rouba
Birrer, Michael J.
Liu, Jinsong http://orcid.org/0000-0002-3239-6658
Zhang, Ningyan http://orcid.org/0000-0002-4348-2180
Lopez-Berestein, Gabriel
de Franciscis, Vittorio
An, Zhiqiang http://orcid.org/0000-0001-9309-2335
Sood, Anil K. http://orcid.org/0000-0003-4242-1762
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-20-1-0335)
Article History
Received: 18 May 2020
Accepted: 22 February 2023
First Online: 26 April 2023
Competing interests
: A.K.S.: Consulting (Merck, Kiyatec, AstraZeneca, Onxeo, Iylon, ImmunoGen, GSK), shareholder (BioPath), research support (M-Trap). N.Z., Z.A., A.K.S., Z.K., and H.D. are inventors for U.S. patent No. 63/004,149 ‘CD5L binding antibodies and uses for the same priority claim’ filed by The University of Texas Systems. The remaining authors declare no competing interests.